

John W Newcomer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8212152/john-w-newcomer-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153
papers

12,331
citations

53
h-index

110
g-index

167
ext. papers

13,606
ext. citations

5.2
avg, IF

6.42
L-index

#	Paper	IF	Citations
153	Reanalysis of a Phase 3 Trial of a Monthly Extended-Release Risperidone Injection for the Treatment of Acute Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 76-77	1.7	0
152	Smoking cessation treatment for individuals with comorbid diabetes and serious mental illness in an integrated health care delivery system. <i>Addictive Behaviors</i> , 2021 , 114, 106697	4.2	3
151	184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers. <i>CNS Spectrums</i> , 2020 , 25, 316-316	1.8	2
150	160 Lurasidone and Metabolic Syndrome: Results from Short- and Long-Term Clinical Studies in Patients with Bipolar Depression. <i>CNS Spectrums</i> , 2020 , 25, 302-303	1.8	4
149	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	39
148	Comorbid Diabetes and Severe Mental Illness: Outcomes in an Integrated Health Care Delivery System. <i>Journal of General Internal Medicine</i> , 2020 , 35, 160-166	4	5
147	Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2020 , 102, 152195	7.3	2
146	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <i>American Journal of Psychiatry</i> , 2020 , 177, 1168-1178	11.9	25
145	Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia. <i>CNS Spectrums</i> , 2020 , 1-11	1.8	2
144	The Eleventh Judicial Circuit Criminal Mental Health Project: Improving Access to Mental Health Treatment in Miami-Dade County. <i>Psychiatric Services</i> , 2020 , 71, 1091-1094	3.3	0
143	Depression and Nicotine Withdrawal Associations with Combustible and Electronic Cigarette Use. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	1
142	F27. EFFICACY OF MONTHLY EXTENDED-RELEASE RISPERIDONE INJECTIONS (RBP-7000) FOR THE TREATMENT OF SCHIZOPHRENIA: AN ANALYSIS OF INDIVIDUAL PANSS ITEMS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S264-S265	1.3	78
141	Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019 , 29, 439-447	2.9	4
140	Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. <i>Journal of Psychiatric Research</i> , 2019 , 114, 67-74	5.2	0
139	Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 428-433	1.7	9
138	Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study. <i>Journal of General Internal Medicine</i> , 2018 , 33, 79-86	4	12
137	Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. <i>Current Medical Research and Opinion</i> , 2018 , 34, 2197-2205	2.5	10

136	Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. <i>BMC Health Services Research</i> , 2018 , 18, 243	2.9	3
135	Diabetes and Prediabetes Prevalence by Race and Ethnicity Among People With Severe Mental Illness. <i>Diabetes Care</i> , 2018 , 41, e119-e120	14.6	11
134	Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2018 , 75, 788-796	14.5	32
133	A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists. <i>Community Mental Health Journal</i> , 2018 , 54, 507-513	2.1	5
132	Rates of Cervical Cancer Screening Among Women With Severe Mental Illness in the Public Health System. <i>Psychiatric Services</i> , 2017 , 68, 839-842	3.3	12
131	Diabetes Prevalence Among Racial-Ethnic Minority Group Members With Severe Mental Illness Taking Antipsychotics: Double Jeopardy?. <i>Psychiatric Services</i> , 2017 , 68, 843-846	3.3	9
130	First-Episode Schizophrenia and Diabetes Risk. <i>JAMA Psychiatry</i> , 2017 , 74, 761-762	14.5	
129	Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics. <i>Psychiatric Services</i> , 2017 , 68, 1280-1287	3.3	1
128	Understanding the Cost of a New Integrated Care Model to Serve CMHC Patients Who Have Serious Mental Illness. <i>Psychiatric Services</i> , 2017 , 68, 990-993	3.3	4
127	Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness. <i>Implementation Science</i> , 2017 , 12, 134	8.4	21
126	Nonpsychiatric Outpatient Care for Adults With Serious Mental Illness in California: Who Is Being Left Behind?. <i>Psychiatric Services</i> , 2017 , 68, 689-695	3.3	9
125	Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review. <i>Journal of General Internal Medicine</i> , 2016 , 31, 1083-91	4	49
124	Glucose Testing for Adults Receiving Medicaid and Antipsychotics: A Population-Based Prescriber Survey on Behaviors, Attitudes, and Barriers. <i>Psychiatric Services</i> , 2016 , 67, 798-802	3.3	4
123	Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 230-8	3.8	27
122	The Role of Clinical Setting and Management Approach in Metabolic Testing Among Youths and Adults Treated With Antipsychotics. <i>Psychiatric Services</i> , 2016 , 67, 128-32	3.3	7
121	Behavioral Weight Loss Treatment in Antipsychotic Treated Youth. <i>Scandinavian Journal of Child and Adolescent Psychiatry and Psychology</i> , 2016 , 4, 96-104	0.6	8
120	Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, 1519-1525	4.6	25
119	Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3418-26	5.6	2

118	Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 386, 2404-12	4.0	151
117	Diabetes Screening Among Underserved Adults With Severe Mental Illness Who Take Antipsychotic Medications. <i>JAMA Internal Medicine</i> , 2015 , 175, 1977-9	11.5	21
116	Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 962-9	3.9	13
115	Association of anxiety disorders and depression with incident heart failure. <i>Psychosomatic Medicine</i> , 2014 , 76, 128-36	3.7	52
114	Treatment of diabetes mellitus: the urgent need for multifactorial interventions. <i>American Journal of Managed Care</i> , 2014 , 20, 357-9	2.1	4
113	Implementation of a weight loss program for Latino outpatients with severe mental illness. <i>Community Mental Health Journal</i> , 2013 , 49, 150-6	2.1	7
112	Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, 1108-20	4.6	31
111	Cognitive deficits, obesity and disability in schizophrenia. <i>Translational Neuroscience</i> , 2012 , 3,	1.2	8
110	Exercise improves physical capacity in obese patients with schizophrenia: pilot study. <i>Schizophrenia Research</i> , 2012 , 141, 284-5	3.6	16
109	Neural correlates of weight gain with olanzapine. <i>Archives of General Psychiatry</i> , 2012 , 69, 1226-37		30
108	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , 2012 , 3, 62	5	19
107	Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 454-62	3.9	20
106	Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 974-80	3.9	43
105	Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, e742-8	4.6	13
104	The general health of people with schizophrenia 2012 , 91-106		
103	The general health of people with schizophrenia 2012 , 91-106		
102	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011 , 10, 138-51	14.4	489
101	Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. <i>American Journal of Medicine</i> , 2011 , 124, 318-24	2.4	49

100	Best practices: implementation of a glucose screening program based on diffusion of innovation theory methods. <i>Psychiatric Services</i> , 2011 , 62, 12-4	3.3	9
99	Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?. <i>BMC Psychiatry</i> , 2011 , 11, 197	4.2	37
98	Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 66-75	2.6	18
97	AuthorsResponse: How can we produce relevant information for decision makers from small area variation studies?. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 782-783	2.6	
96	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011 , 10, 52-77	14.4	1288
95	Risks from antipsychotic medications in children and adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 729; author reply 730	27.4	1
94	Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. <i>Archives of General Psychiatry</i> , 2010 , 67, 17-24		159
93	Metabolic screening in children receiving antipsychotic drug treatment. <i>JAMA Pediatrics</i> , 2010 , 164, 344-51		112
92	A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 425-30	1.7	20
91	Metabolic screening and treatment preferences of Hispanic inpatients. <i>Psychiatric Services</i> , 2010 , 61, 1162-3	3.3	3
90	Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. <i>Diabetes Care</i> , 2009 , 32, 1037-42	14.6	133
89	Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. <i>American Journal of Psychiatry</i> , 2009 , 166, 345-53	11.9	138
88	The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 791-9	2.6	81
87	Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 26-32	1.7	28
86	Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. <i>Medical Journal of Australia</i> , 2009 , 190, S39-42	4	86
85	A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 487-99	4.6	46
84	Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. <i>Journal of Clinical Psychiatry</i> , 2009 , 70 Suppl 3, 30-6	4.6	32
83	Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. <i>Schizophrenia Research</i> , 2008 , 106, 300-7	3.6	19

82	Review: children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible to adverse events. <i>Evidence-Based Mental Health</i> , 2008 , 11, 81	11.1	2
81	Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. <i>Neuropsychopharmacology</i> , 2008 , 33, 985-94	8.7	61
80	A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1046-56	4.6	89
79	Addressing cardiometabolic risk during treatment with antipsychotic medications. <i>Current Opinion in Psychiatry</i> , 2008 , 21, 613-8	4.9	22
78	Introduction: Cardiovascular Disease and Metabolic Risk Factors in Patients with Mental Illness. <i>CNS Spectrums</i> , 2008 , 13, 3-4	1.8	3
77	Conclusion: Summary and Recommendations. <i>CNS Spectrums</i> , 2008 , 13, 13-14	1.8	5
76	Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 316-22	4.6	77
75	Introduction: cardiovascular disease and metabolic risk factors in patients with mental illness. <i>CNS Spectrums</i> , 2008 , 13, 1-14	1.8	1
74	Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendations. <i>CNS Spectrums</i> , 2008 , 13, 13-4	1.8	1
73	Antipsychotic Medication-Induced Weight Gain and Risk for Diabetes and Cardiovascular Disease 2007 , 223-245		1
72	Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. <i>Neuropsychopharmacology</i> , 2007 , 32, 2561-9	8.7	36
71	Severe mental illness and risk of cardiovascular disease. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 1794-6	27.4	286
70	Comparing safety and tolerability of antipsychotic treatment. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, e07	4.6	12
69	Challenges and solutions to integrating mental and physical health care. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, e09	4.6	57
68	Series introduction and cardiovascular disease in patients with schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, e12	4.6	50
67	Identifying metabolic risks with antipsychotics and monitoring and management strategies. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, e17	4.6	57
66	Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. <i>Journal of Clinical Psychiatry</i> , 2007 , 68 Suppl 1, 20-7	4.6	90
65	Evidence of switching antipsychotic therapy to improve metabolic disturbances. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, e13	4.6	

64	Antipsychotic medications: metabolic and cardiovascular risk. <i>Journal of Clinical Psychiatry</i> , 2007 , 68 Suppl 4, 8-13	4.6	115
63	Metabolic syndrome and mental illness. <i>American Journal of Managed Care</i> , 2007 , 13, S170-7	2.1	123
62	The metabolic effects of antipsychotic medications. <i>Canadian Journal of Psychiatry</i> , 2006 , 51, 480-91	4.8	196
61	Medical Risk in Patients With Bipolar Disorder and Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, e16	4.6	112
60	Medical risk in patients with bipolar disorder and schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006 , 67 Suppl 9, 25-30; discussion 36-42	4.6	28
59	Medical risk in patients with bipolar disorder and schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, e16	4.6	21
58	Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention. <i>CNS Drugs</i> , 2005 , 19, 1-11	6.7	522
57	Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <i>CNS Drugs</i> , 2005 , 19 Suppl 1, 1-93	6.7	662
56	Metabolic and Endocrine Disturbances in Psychiatric Disorders: A Multidisciplinary Approach to Appropriate Atypical Antipsychotic Utilization. <i>CNS Spectrums</i> , 2005 , 10, 1-16	1.8	2
55	Clinical Considerations in Selecting and Using Atypical Antipsychotics. <i>CNS Spectrums</i> , 2005 , 10, 12-19	1.8	5
54	Metabolic and Endocrine Disturbances in Psychiatric Disorders: A Multidisciplinary Approach to Appropriate Atypical Antipsychotic Utilization. <i>CNS Spectrums</i> , 2005 , 10, 819a-819l	1.8	1
53	Reply: Plasma Leptin and Antipsychotic-Induced Body Weight Gain. <i>Neuropsychopharmacology</i> , 2005 , 30, 1770-1771	8.7	2
52	Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. <i>Neuropsychopharmacology</i> , 2005 , 30, 184-91	8.7	58
51	Effects of glucocorticoids on declarative memory function in major depression. <i>Biological Psychiatry</i> , 2004 , 55, 811-5	7.9	62
50	Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. <i>Schizophrenia Research</i> , 2004 , 71, 137-44	3.6	17
49	Metabolic risk during antipsychotic treatment. <i>Clinical Therapeutics</i> , 2004 , 26, 1936-46	3.5	94
48	Effects of dexamethasone on declarative memory function in posttraumatic stress disorder. <i>Psychiatry Research</i> , 2004 , 129, 1-10	9.9	39
47	The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, S1-6	1.7	90

46	Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, S7-14	1.7	97
45	Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004 , 65 Suppl 7, 4-18; quiz 19-20	4.6	55
44	Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. <i>Journal of Clinical Psychiatry</i> , 2004 , 65 Suppl 18, 36-46	4.6	26
43	Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. <i>Psychoneuroendocrinology</i> , 2003 , 28, 809-22	5	204
42	Managing Psychosis in Long-Term Care: Treating the Whole Patient. <i>Journal of the American Medical Directors Association</i> , 2003 , 4, H2-H7	5.9	
41	Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. <i>Archives of General Psychiatry</i> , 2002 , 59, 337-45		424
40	Does cognitive function improve with quetiapine in comparison to haloperidol?. <i>Schizophrenia Research</i> , 2002 , 53, 239-48	3.6	159
39	Abnormalities in glucose regulation associated with mental illness and treatment. <i>Journal of Psychosomatic Research</i> , 2002 , 53, 925-33	4.1	49
38	NMDA receptor regulation of memory and behavior in humans. <i>Hippocampus</i> , 2001 , 11, 529-42	3.5	205
37	Risperidone-associated diabetic ketoacidosis. <i>Psychosomatics</i> , 2001 , 42, 279-80	2.6	26
36	Glucocorticoid effects on memory function over the human life span. <i>Development and Psychopathology</i> , 2001 , 13, 491-513	4.3	78
35	Cognitive Neuroendocrinology. <i>Critical Issues in Neuropsychology</i> , 2001 , 5-24		
34	Glutamatergic transmission. <i>Pharmaceutical Science Series</i> , 2001 , 385-406		
33	Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. <i>Archives of General Psychiatry</i> , 2000 , 57, 1165-73		126
32	NMDA receptor function, memory, and brain aging. <i>Dialogues in Clinical Neuroscience</i> , 2000 , 2, 219-32	5.7	97
31	Glycine agonists: what can they teach us about schizophrenia?. <i>Archives of General Psychiatry</i> , 1999 , 56, 13-7		52
30	Glucose-induced increase in memory performance in patients with schizophrenia. <i>Schizophrenia Bulletin</i> , 1999 , 25, 321-35	1.3	68
29	Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. <i>Archives of General Psychiatry</i> , 1999 , 56, 1135-40		247

28	NMDA receptor hypofunction model of schizophrenia. <i>Journal of Psychiatric Research</i> , 1999 , 33, 523-33	5.2	786
27	Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. <i>Neuropsychopharmacology</i> , 1999 , 20, 106-18	8.7	442
26	Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. <i>Neuroendocrinology</i> , 1999 , 70, 146-52	5.6	134
25	Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. <i>Psychiatry Research</i> , 1999 , 88, 1-13	9.9	45
24	Glucocorticoid interactions with memory function in schizophrenia. <i>Psychoneuroendocrinology</i> , 1998 , 23, 65-72	5	35
23	The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. <i>Progress in Brain Research</i> , 1998 , 116, 421-37	2.9	121
22	Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. <i>Archives of General Psychiatry</i> , 1998 , 55, 995-1000		107
21	Robust leptin secretory responses to dexamethasone in obese subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3230-3	5.6	117
20	Robust Leptin Secretory Responses to Dexamethasone in Obese Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3230-3233	5.6	95
19	Hippocampal MR imaging morphometry by means of general pattern matching. <i>Radiology</i> , 1996 , 199, 787-91	20.5	77
18	Memory improvement following induced hyperinsulinemia in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1996 , 17, 123-30	5.6	369
17	The effects of chronic corticosterone on memory performance in the platform maze task. <i>Physiology and Behavior</i> , 1996 , 59, 1111-5	3.5	17
16	Platelet serotonin markers and depressive symptomatology. <i>Biological Psychiatry</i> , 1995 , 37, 442-7	7.9	55
15	Commonly used therapeutic doses of glucocorticoids impair explicit memory. <i>Annals of the New York Academy of Sciences</i> , 1995 , 761, 400-2	6.5	41
14	Glucocorticoid-induced impairment in declarative memory performance in adult humans. <i>Journal of Neuroscience</i> , 1994 , 14, 2047-53	6.6	379
13	Are there neurochemical indicators of risk for schizophrenia?. <i>Schizophrenia Bulletin</i> , 1994 , 20, 75-88	1.3	10
12	Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. <i>Psychopharmacology</i> , 1994 , 116, 291-6	4.7	10
11	Chronic corticosterone treatment impairs spontaneous alternation behavior in rats. <i>Behavioral and Neural Biology</i> , 1994 , 61, 186-90		48

10	Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. <i>British Journal of Psychiatry</i> , 1994 , 164, 834-8	5.4	23
9	Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. <i>European Journal of Pharmacology</i> , 1993 , 230, 245-50	5.3	30
8	Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: A longitudinal study.. <i>Behavioral Neuroscience</i> , 1993 , 107, 926-940	2.1	158
7	Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. <i>Psychopharmacology</i> , 1993 , 110, 145-51	4.7	33
6	Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. <i>Psychiatry Research</i> , 1992 , 41, 191-202	9.9	20
5	Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. <i>Biological Psychiatry</i> , 1991 , 29, 855-64	7.9	53
4	Left-handedness in male schizophrenic patients is associated with increased impairment on the Luria-Nebraska Neuropsychological Battery. <i>Biological Psychiatry</i> , 1991 , 30, 326-34	7.9	15
3	Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. <i>Psychiatry Research</i> , 1990 , 31, 243-50	9.9	39
2	Antipsychotic Therapies and Glucose Dysregulation in the Mental Illness Population657-663		
1	Metabolic Adverse Effects Associated with Antipsychotic Medications577-597		